Precigen (PGEN) Sees Over 50% Upside Potential on Strong Papzimeos Launch

Key Facts

1Precigen (PGEN) maintains a Buy rating with Q1 revenues expected to exceed $18M.

2Management guides for cash flow breakeven in 2026.

3Scenario analysis yields a fair value between $6.13 and $7.01 per share, implying over 50% upside.

Precigen (PGEN) is maintaining a Buy rating following the successful commercial launch of its FDA-approved drug, Papzimeos. Management expects first-quarter revenues to exceed $18 million, driven by robust payer acceptance and strong market demand. This positive momentum has led to a revised financial outlook, with the company guiding for cash flow breakeven by 2026. Scenario analysis suggests a fair value for the stock between $6.13 and $7.01, representing a potential upside of more than 50% from current levels. The successful rollout of Papzimeos is seen as a critical catalyst for the company's long-term growth and valuation. Investors are closely monitoring the company's ability to maintain this revenue run rate as it moves toward profitability.

Open on chart